These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31543154)

  • 1. Complement inhibitors are not useful in secondary hemolytic uremic syndromes.
    Duineveld C; Wetzels JFM
    Kidney Int; 2019 Oct; 96(4):829-833. PubMed ID: 31543154
    [No Abstract]   [Full Text] [Related]  

  • 2. Complement inhibitors are useful in secondary hemolytic uremic syndromes.
    Caravaca-Fontan F; Praga M
    Kidney Int; 2019 Oct; 96(4):826-829. PubMed ID: 31543153
    [No Abstract]   [Full Text] [Related]  

  • 3. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR; Johnson S
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HUS and the case for complement.
    Conway EM
    Blood; 2015 Oct; 126(18):2085-90. PubMed ID: 26396094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the management of atypical hemolytic uremic syndrome.
    Cataland SR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):537-9. PubMed ID: 23073053
    [No Abstract]   [Full Text] [Related]  

  • 9. Shiga toxin associated hemolytic uremic syndrome.
    Keir LS
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):525-39. PubMed ID: 26043390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside.
    Orth-Höller D; Riedl M; Würzner R
    EMBO Mol Med; 2011 Nov; 3(11):617-9. PubMed ID: 21954211
    [No Abstract]   [Full Text] [Related]  

  • 12. Early initiation of eculizumab therapy for Streptococcus pneumoniae-associated hemolytic uremic syndrome.
    See J; Bou Matar R; Baloglu O; Latifi SQ; Talati R; Agarwal HS
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28589. PubMed ID: 32672848
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
    Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC
    Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Hematol; 2010 Sep; 17(5):432-8. PubMed ID: 20613506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.
    Ahlenstiel-Grunow T; Hachmeister S; Bange FC; Wehling C; Kirschfink M; Bergmann C; Pape L
    Nephrol Dial Transplant; 2016 Jul; 31(7):1114-21. PubMed ID: 27190382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab therapy.
    Cataland SR
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.